Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide

Core Points - Lisata Therapeutics has received a new composition of matter patent for certepetide, extending IP protection until March 2040, with potential for further extension [1][2] - The patent secures exclusive rights to certepetide, preventing others from manufacturing or selling the drug, thus significantly enhancing the company's IP portfolio [2][3] - The CEO of Lisata highlighted that this patent milestone boosts the value of certepetide and the company, delaying generic competition for nearly two decades and supporting commercialization efforts [3] Company Overview - Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases [5] - Certepetide is designed to enhance the delivery of anti-cancer drugs to solid tumors by activating a novel uptake pathway, showing promise in improving treatment efficacy [4][5] - The company has established significant partnerships and expects to announce multiple milestones in the next 1.5 years, with sufficient capital projected to fund operations into Q4 2026 [5]